Market research
SMSPHARMA.NSE SMS Pharmaceuticals Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 41B
- P/E ratio
- 39.71
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.28
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- INE812G01025
- Market cap
- 41B
- P/E ratio
- 39.71
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.28
About
About SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Research context
SMS Pharmaceuticals Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SMSPHARMA.NSE discussion.
5 years, 6 months ago
SMS Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 40.6% above its 200 day moving average.
From a valuation standpoint, the stock is 54.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
SMS Pharmaceuticals Limited's total revenue rose by 85.0% to $1B since the same quarter in the previous year.
Its net income has increased by 180.9% to $214M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.3% to $349M since the same quarter in the previous year.
Based on the above factors, SMS Pharmaceuticals Limited gets an overall score of 5/5.